Berkeley Heights-based Cyclacel Pharmaceuticals Inc. announced Friday the pricing of its public offering of 2.857 million shares of common stock at a price of $3.50 per share.
According to the announcement, the company expects to receive approximately $10 million from the offering.
Cyclacel has granted underwriters a 30-day option to purchase up to an additional 428,571 shares of stock. Laidlaw & Company Ltd. is the sole bookrunning manager for the offering, the company said in a recent press release.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy